Trial Profile
An Open-label, Phase 2a Trial to Evaluate the Effect of Escalating Doses of IW-1973 on Tolerability, Endothelial Function, and Hemodynamics in Patients With Stable Type 2 Diabetes and Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Praliciguat (Primary)
- Indications Hypertension in diabetes
- Focus Adverse reactions; Pharmacodynamics; Proof of concept; Therapeutic Use
- Sponsors Ironwood Pharmaceuticals
- 30 Oct 2019 According to a Cyclerion Therapeutics Media release, company will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the topline results from the Phase 2 proof-of-concept studies of praliciguat.
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 04 Dec 2017 Topline results presented in an Ironwood Pharmaceuticals media release.